The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

We recently compiled a list of the 10 Best UK Stocks to Invest in Now. In this article, we are going to take a look at where ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

Additionally, AstraZeneca increased its guidance for the fiscal year ... In another report released today, Barclays also maintained a Buy rating on the stock with a £140.00 price target. TipRanks ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.

Four analysts surveyed by Zacks expected $13.04 billion. Astrazeneca shares have decreased nearly 4% since the beginning of the year. The stock has climbed 1% in the last 12 months.

Shares of AstraZeneca PLC AZN inched up 0.05% to £99.90 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 1.22% to 8,025.77.

The data showed that Koselugo met its primary endpoint, demonstrating a statistically significant and clinically meaningful ...